Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy

Fig. 5

Identification of potential biomarkers, differentially expressed in PARPis- sensitive and resistant AsPCs and their matched HGSOC tumors. Protein expression analysis of the seven genes c-Met, CDKN2A, P-glyc, N-cadherin, FANCF, SPRY2, and E-cadherin in HGSOC tumor samples, matched to PARPis-sensitive and resistant AsPCs. a–d c-Met, CDKN2A, P-glyc and N-cadherin staining patterns in representative cores in epiploon (EP), left ovary (LO) and right ovary (RO) tumors, comparing sensitive (top) vs. resistant (bottom) tissue samples. e–g FANCF, SPRY2 and E-cadherin staining patterns in representative cores in epiploon (EP), left ovary (LO) and right ovary (RO) tumors, comparing sensitive (top) vs. resistant (bottom) tissue samples. Box-plot representation of the protein expression levels in sensitive vs. resistant ovarian tissues are presented next to each of the TMAs. The Wilcoxon two-sample test was used for statistical analysis. All values were expressed as the means ± S.D. *p < 0.05 **p < 0.01 and ***p < 0.001

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us